Are Investigational New Drug Trials in India A Positive Sign For Healthcare
Are Investigational New Drug Trials in India A Positive Sign For Healthcare: The Researchers Perspective
The New Drugs and Clinical Trials Rules, 2019 was declared by the ministry of health and family welfare on 25th March 2019 (GSR Notification #227). The key focus of the new set of rules is to encourage advances in clinical research in India. The rules are meant to revolutionize the regulatory aspects for the conduct of clinical trials and the subsequent approval of new drugs. The New Drugs and Clinical Trials Rules, 2019 has been effective from 25th March 2019; however, the chapter four of the rules which pertains to “Ethics committee for biomedical and health research” came into action from 21st September 2019.
The new rules supersede Part XA and Schedule Y of Drugs and Cosmetics Rules and are applicable to all new drugs, investigational new drugs (INDs) for human use, clinical trial, bioequivalence/bioavailability study and ethics committee.
The application fees have been hiked for Phase 1 to 4 clinical trials. Additionally, application and approval formats have been modified. Some of the modified forms are mentioned below:
To bring in more clarity, many definitions have been newly incorporated, while some have been modified. As per the new definition, an orphan drug is defined as drug used to treat condition which affects not more than 5 lac persons in India.
For the review and approval of clinical trial (CT) applications, fixed timelines have been put down.
been introduced. If no response is received from the central licencing authority to the applicant within the said period (30 days), the permission to conduct clinical trial shall be deemed to have been granted by the central licencing authority. In such cases, before trial initiation the applicant is required to inform the central licencing authority in Form CT-4A; the central licencing authority on the basis of the said
The new rules have incorporated significant changes in the constitution of ethics committee (EC). As per the new rules, the ethics committee should have a minimum of seven members from medical, non-medical, scientific and non-scientific areas with.
At least 50% of members should not be affiliated with the institute or organization in which EC is constituted and every member of the EC shall be required to undergo such training and development programs.
Two types of ethics committee have been defined:
Ethics committee registration certificate would be granted in Form CT-02 within a period of 45 working days. The validity of registration has been increased to a period of five years from the date of its issue. Application for the renewal of the registration can be submitted 90 days prior to the date of the expiry of the registration to ensure deemed continuity. As per the new rule, when a clinical trial site does not have its own EC, clinical trial at that site may be initiated after obtaining approval of the protocol from the EC of another trial site; however, in such cases the approving ethics committee should take responsibility for the study at another site or center and the approving ethics committee should be located within the same city or within the radius of 50 kilometres of the clinical trial site.
New Drugs and Clinical Trials Rules, 2019, Ministry of Health & Fam. Welfare, Notification, G.S.R. 227(E), (March 19, 2019).